

**PATENT**  
**REEL: 017366 FRAME: 0674**

## ASSIGNMENT

**WHEREAS**, Aventis Pharma Deutschland GmbH, legal successor of Aventis Research & Technologies GmbH & Co. KG, a corporation organized under and pursuant to the laws of Germany having its principal place of business at D-65926 Frankfurt am Main; GERMANY (hereinafter referred to as Assignor), is the sole and exclusive owner, by assignment, of the Patents listed in *Schedule A*; and


**WHEREAS**, Covion Organic Semiconductors GmbH, a Corporation organized under and pursuant to the laws of Germany having its principal place of business at Industriepark Höchst, D-65926 Frankfurt, GERMANY (hereinafter referred to as Assignee), is desirous of acquiring the right, title and interest in, to and under said Patent Applications and the invention covered thereby;

NOW, THEREFORE, for good and valuable good and valuable consideration, receipt of which is hereby acknowledged, the said Assignor has sold, assigned, transferred and set over, and does hereby sell, assign, transfer and set over to the said Assignee, the entire right, title and interest for the United States of America and all other countries in and to said applications for all original, divisional, continuation, continuation-in-part, substitute or reissue applications and patents applied for or granted therefore in the United States of America and all other countries on the attached list of *Schedule A*, and the Commissioner of Patents and Trademarks is hereby authorized and requested to issue all patents on *Schedule A* to said assignee herein, as assignee of the entire interest therein; and the undersigned for itself and its legal representatives, heirs and assigns does hereby agree and covenant without further remuneration, to execute and deliver all divisional, continuation, continuation-in-part, reissue and other applications for Letters Patent and all assignments thereof to said assignee or its assigns, to communicate to said assignee or its representatives all facts known to the undersigned respecting said invention listed on *Schedule A* whenever requested, to testify in any interferences or other legal proceedings in which said application or patent may become involved, to sign all lawful papers, make all rightful oaths, and do generally everything necessary to aid assignee, its successors, assigns and nominees to obtain patent protection for said invention listed on *Schedule A* in the United States of America and all other countries, the expenses incident to said patents listed on *Schedules A* to be borne and paid by said assignee.

Dated: 31 August 2005

Aventis Pharma Deutschland GmbH

  
ppa. Dr. Dirk Kruse

  
i.V. Dr. Jürgen Gramlich

# **SCHEDULE A**

**5,885,368**

**6,414,431**

**6,211,369**

**6,316,591**

**6,335,480**

**6,822,094**